This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire

Safety Review Committee endorses escalation to 160 mg TUS dosing

Cohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities

Excellent safety and complete remissions (CRs) in some of the most difficult-to-treat AML populations

No dose reductions required to the standard-of-care VEN/AZA with TUS dose cohorts

TUS+VEN+AZA triplet continues to achieve CRs and minimal residual disease (MRD)-negativity with favorable safety in newly diagnosed AML patients

Aptose receives third advance under the Loan Agreement with Hanmi Pharmaceutical

SAN DIEGO and TORONTO

See Full Page